

AXIRON LAUNCHED BY ELI LILLY IN GERMANY

Highlights:

- **Axiron® launched by Eli Lilly in Germany**
- **Testosterone therapy market in Germany is the second largest outside the US**

Acrux (ASX: ACR) today confirmed that Axiron® has now launched in Germany for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). Germany is the second largest testosterone market outside of the US, after Canada. Axiron is now launched in US, Canada, Australia, Brazil and Germany.

Acrux Executive Chairman Ross Dobinson commented “We have a very capable and committed marketing partner in Eli Lilly, and we are pleased to announce another milestone in the international commercialisation of Axiron.”

Contact

Ross Dobinson, Executive Chairman: 03 9691 5920

About Acrux

www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including Axiron®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.